Clinical trial
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating…
NCT00028717 · Commissie Voor Klinisch Toegepast Onderzoek, Other · Unknown status
Key facts
| NCT number | NCT00028717 |
|---|---|
| Title | Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma |
| Official title | A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma |
| Lead sponsor | Commissie Voor Klinisch Toegepast Onderzoek, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate |
| Enrollment | 400 |
| Start date | Feb 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 17, 2013 |
| Countries | Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: